A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine.

Trial Profile

A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Nabiximols (Primary)
  • Indications CNS disorders; Multiple sclerosis; Peripheral nerve injuries; Spinal cord disorders
  • Focus Adverse reactions; Registrational
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top